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Supplementary information: 
PI16 peptide sequence was analysed using several online prediction tools to determine its putative structure. 
Most of the tools used suggest the presence of a signal peptide (aa 1 to 28) and a terminal transmembrane 
domain (amino acids 442-463). The output from http://topcons.cbr.su.se/pred/ is below (Tsirigos KD, Peters 
C, Shu N, Käll L, & Elofsson A (2015) The TOPCONS web server for consensus prediction of membrane 
protein topology and signal peptides. Nucleic Acids Res. 43(W1):W401-W407.), showing the regions 
predicted to be inside the cell in red and outside in blue, then the consensus from the 6 different models 
underneath: 
 
 Supplementary Fig. 1. Putative tertiary structure of PI16. (A) Predicted PI16 domain structure. (B) 
Predicted protein structure of full length PI16, output from RaptorX prediction software 
http://raptorx.uchicago.edu/StructurePrediction/predict/ (Källberg M, et al. (2012) Template-based protein 
structure modeling using the RaptorX web server. Nat. Protocols 7(8):1511-1522.). (C) Based on a consensus 
from the prediction software, we have created a schematic of the putative structure of PI16.  
 
 Supplementary Fig. 2. HCAECs express four PI16 isoforms. Four splice forms were isolated during the 
cloning of PI16. Isoform 1: the full length version. Isoform 2: a previously documented splice form that lacks 
the majority of exon 5, but uses a splice site that maintains the reading frame to retain the putative 
transmembrane domain. Isoform 3: is expressed at similar levels to isoform 1 and 2, but uses an alternative 
splice donor sites, including a further 4 base pairs that causes frame shift and alternative terminal amino acid 
sequence.  Isoform 4: is the least abundant isoform in HCAECs (Supplementary Fig. 3, below), utilises an 
alternative proximal splice donor site and distal splice acceptor site with the same frame shift as isoform 3, 
thus sharing the same 12 terminal amino acids. With respect to isoform 3 and 4, an absence of the putative 





Protein sequence of different splice forms of PI16. Sections of sequence are coloured to highlight regions 
lost during alternative splicing 



























3               MHGSCSFLMLLLPLLLLLVATTGPVGALTDEEKRLMVELHNLYRAQVSPTASDMLHMRWD 
4               MHGSCSFLMLLLPLLLLLVATTGPVGALTDEEKRLMVELHNLYRAQVSPTASDMLHMRWD 
1               MHGSCSFLMLLLPLLLLLVATTGPVGALTDEEKRLMVELHNLYRAQVSPTASDMLHMRWD 
2               MHGSCSFLMLLLPLLLLLVATTGPVGALTDEEKRLMVELHNLYRAQVSPTASDMLHMRWD 
                ************************************************************ 
 
3               EELAAFAKAYARQCVWGHNKERGRRGENLFAITDEGMDVPLAMEEWHHEREHYNLSAATC 
4               EELAAFAKAYARQCVWGHNKERGRRGENLFAITDEGMDVPLAMEEWHHEREHYNLSAATC 
1               EELAAFAKAYARQCVWGHNKERGRRGENLFAITDEGMDVPLAMEEWHHEREHYNLSAATC 
2               EELAAFAKAYARQCVWGHNKERGRRGENLFAITDEGMDVPLAMEEWHHEREHYNLSAATC 
                ************************************************************ 
 
3               SPGQMCGHYTQVVWAKTERIGCGSHFCEKLQGVEETNIELLVCNYEPPGNVKGKRPYQEG 
4               SPGQMCGHYTQVVWAKTERIGCGSHFCEKLQGVEETNIELLVCNYEPPGNVKGKRPYQEG 
1               SPGQMCGHYTQVVWAKTERIGCGSHFCEKLQGVEETNIELLVCNYEPPGNVKGKRPYQEG 
2               SPGQMCGHYTQVVWAKTERIGCGSHFCEKLQGVEETNIELLVCNYEPPGNVKGKRPYQEG 
                ************************************************************ 
 
3               TPCSQCPSGYHCKNSLCEPIGSPEDAQDLPYLVTEAPSFRATEASDSRKMG--------- 
4               TPCSQCPSGYHCKNSLCEPIGSPEDAQDLPYLV--------------------------- 
1               TPCSQCPSGYHCKNSLCEPIGSPEDAQDLPYLVTEAPSFRATEASDSRKMGTPSSLATGI 
2               TPCSQCPSGYHCKNSLCEPIGSPEDAQDLPYLVTEAPSFRATEASDSRKMG--------- 
                *********************************                            
 
3               ------------------------------------------------------------ 
4               ------------------------------------------------------------ 
1               PAFLVTEVSGSLATKALPAVETQAPTSLATKDPPSMATEAPPCVTTEVPSILAAHSLPSL 
2               ------------------------------------------------------------ 
                                                                             
 
3               ------------------------------------------------------------ 
4               ------------------------------------------------------------ 
1               DEEPVTFPKSTHVPIPKSADKVTDKTKVPSRSPENSLDPKMSLTGARELLPHAQEEAEAE 
2               ------------------------------------------------------------ 
                                                                             
 
3               ------------------------------------------------------------ 
4               ------------------------------------------------------------ 
1               AELPPSSEVLASVFPAQDKPGELQATLDHTGHTSSKSLPNFPNTSATANATGGRALALQS 
2               ------------------------------------------------------------ 
                                                                             
 
3               ------------TPSSLATGIPAFLVTEVQRALTSLASCQG-- 
4               -----------------------------QRALTSLASCQG-- 
1               SLPGAEGPDKPSVVSGLNSGPGHVWGPLLGLLLLPPLVLAGIF 
2               ----AEGPDKPSVVSGLNSGPGHVWGPLLGLLLLPPLVLAGIF 
                                                * .     *   
 
 
The highlighted T represents a frequently observed polymorphism T50P caused by an A-C single nucleotide 
polymorphism of varying frequency and unknown significance, the 1000 genome frequency data is below: 
 
ALL 
A: 43%C: 57% 
AFR 
A: 22%C: 78% Sub-populations 
AMR 
A: 46%C: 54% Sub-populations 
ASN 
A: 46%C: 54% Sub-populations 
EUR 




 Supplementary Fig. 3. Analysis of isoform expression. (A) RT-qPCR analysis reveals that shear stress 
regulates the transcript expression of all four PI16 isoforms (Ai, isoform 1; Aii, isoform 2; Aiii, isoform 3; 
Aiv, isoform 4) expressed as copy number per ng of input RNA. (B) Western blot analysis cell lysates or 
conditioned media from CHO cells over expressing isoforms 1-4 by transient transfection, reveal the all four 
isoforms can be both cell bound and found in conditioned media. The blot also contains cell extract from 
HCAEC cells cultured under ESS (LSS75_cell lysate). Comparison of the CHO lysates with the HCAEC 
LSS75_cell lysate, suggests that the majority of the PI16 present in the HCAEC cell extract is the full length 
(molecular weight approximately 68KDa, isoform 1) but with an additional band at approximately 40KDa 
which may represent a larger molecular weight form seen in CHO transfections of isoforms 2 and/or 3. This 
is consistent with the qPCR data where isoform 1, 2 and 3 are highly expressed.  
 Supplementary Fig. 4. PI16 expression in human coronary arteries. Human coronary arteries were 
stained for PI16 and UEA as described in the methods. Additionally, serial sections were also stained with 
mouse anti-human smooth muscle cell actin (Dako, clone 1A4). The intimal cells that stained positive for 
PI16 were also SMC-actin positive; however not all intimal smooth muscle cells were positive for PI16 (B). 
C-E) Adventitial microvessel had comparatively low levels of PI16 staining in endothelial cells, with very 
strong staining in smooth muscle cells, suggesting microvascular endothelial cells do not express PI16 at the 

























Supplementary Fig. 5. PI16 expression in human coronary arteries. Repeat of Figure 1C, showing 






SW611F  ATGTGCGGCCACTACACGCA 
SW612R CCTTCACGTTCCCCGGAGGC 
SW625F  CCTCCGGGGAACGTGAAGGG 
SW626R  TCAGTCGCCCGGAAGGATGG 
SW627F  TAATGCCACGGGTGGGCGTG 
SW628R  TTCAGCCCTGACACGACGCT 
Cloning primer: Forward creates BglII site and optimises Kozak sequence, reverse introduces NheI site: 
SW653F GAGAGATCTCTGGCCACCATGCACGGCTCC  
SW654R  GAGTGCTAGCCCCTTCAGAAGATTCCAGCC 
 
SW773F/SW774R PI16 cloning primers for N-terminal GST fusion introduces BamHI sites at both ends, 5’ 
end in frame with coding sequence. 
SW773F GATCTGGATCCTCCATGCACGGCTCCTGCAG 
SW774R CCAGAATTCTAGCCCCTTCAGAAGATTCCAG 
SW775F pGEX-6p-1 sequencing primer: GTATATAGCATGGCCTTTGC 
 
 
 
 
 
